Venus Remedies has extended its footprint in Latin America with marketing authorisation for meropenem from Venezuela, a $6-billion pharmaceutical market.
Pawan Chaudhary, Chairman and Managing Director, Venus Remedies said, “We are planning to launch meropenem in Venezuela in the next couple of months. The $10-million meropenem market in Venezuela offers a great opportunity to us and we are aiming at capturing a sizeable share in this market in the first year of the launch. Having a presence in important Latin American markets like Columbia, Peru, Guatemala and Mexico, we are constantly strengthening our position in Latin America.”
Meropenem, which accounts for annual global sales of $906 million which are estimated to go up to $1,006 million in the next one year, is an off-patented antibacterial agent of the carbapenem class of antibiotics, which caters to diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.
EP News Bureau – Mumbai